Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Weber

Showing results (241-250 of 341) with videos related to

Pageof 35
Sort By:
Hypertension (Dallas, Tex. : 1979)|October 18, 2022
Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled HypertensionDagmara Hering, David Nikoleishvili, Avtandil Imedadze, et al.
Journal of Human Hypertension|December 11, 2023
Emerging Authors Program for building cardiovascular disease prevention and management research capacity in low- and middle-income countries: a collaboration of the U.S. Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension LeagueDinesh Neupane, Qaiser Mukhtar, Elizabeth Kay Krajan Pardo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 14, 2022
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trialKazuomi Kario, Felix Mahfoud, David E Kandzari, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 10, 2016
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH SubstudyMichael A Weber, Michael Bloch, George L Bakris, et al.
Circulation|October 26, 2018
Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED TrialKazuomi Kario, Michael Böhm, Felix Mahfoud, et al.
JACC. Cardiovascular Interventions|February 22, 2020
The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of HypertensionMichael A Weber, Ajay J Kirtane, Matthew R Weir, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 10, 2020
Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian designMichael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 9, 2020
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian designMichael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
Hypertension (Dallas, Tex. : 1979)|June 23, 2023
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm HgSondre Heimark, Maria H Mehlum, Giuseppe Mancia, et al.
Pageof 35

Showing results (241-250 of 341) with videos related to

Sort By:
Pageof 35
Hypertension (Dallas, Tex. : 1979)|October 18, 2022
Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled HypertensionDagmara Hering, David Nikoleishvili, Avtandil Imedadze, et al.
Journal of Human Hypertension|December 11, 2023
Emerging Authors Program for building cardiovascular disease prevention and management research capacity in low- and middle-income countries: a collaboration of the U.S. Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension LeagueDinesh Neupane, Qaiser Mukhtar, Elizabeth Kay Krajan Pardo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 14, 2022
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trialKazuomi Kario, Felix Mahfoud, David E Kandzari, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 10, 2016
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH SubstudyMichael A Weber, Michael Bloch, George L Bakris, et al.
Circulation|October 26, 2018
Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED TrialKazuomi Kario, Michael Böhm, Felix Mahfoud, et al.
JACC. Cardiovascular Interventions|February 22, 2020
The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of HypertensionMichael A Weber, Ajay J Kirtane, Matthew R Weir, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 10, 2020
Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian designMichael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 9, 2020
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian designMichael Böhm, Raymond R Townsend, Kazuomi Kario, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
Hypertension (Dallas, Tex. : 1979)|June 23, 2023
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm HgSondre Heimark, Maria H Mehlum, Giuseppe Mancia, et al.
Pageof 35